# Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

> **NCT01902225** · PHASE1 · COMPLETED · sponsor: **Weiyun Ai** · enrollment: 24 (actual)

## Conditions studied

- Lymphoma
- T-Cell Lymphoma
- Cutaneous Lymphoma

## Interventions

- **DRUG:** Istodax
- **DRUG:** Doxil

## Key facts

- **NCT ID:** NCT01902225
- **Lead sponsor:** Weiyun Ai
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-04
- **Primary completion:** 2018-07-13
- **Final completion:** 2020-04-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01902225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01902225, "Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01902225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*